1. Home
  2. Directory
  3. New York
  4. New York New York
  5. Psychiatry Neurology
  6. NPI Profile
  7. Prescriptions 1205096310

DR. YAKOV ISAKOV
Prescription History 1205096310
Psychiatry & Neurology - Neurology in New York, NY

NPI Status: Active since June 11, 2008

Contact Information

710 W 168TH ST
1-15
NEW YORK, NY
ZIP 10032
Phone: (212) 305-5703
Fax: (212) 305-6978

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. YAKOV ISAKOV, an active Neurology specialist practicing in New York, NY. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 85 documented patient claims. Among these therapy options, the most frequently utilized medication is Glatiramer Acetate, which accounts for 34 claims alone.

Medication Index

B
D
G
No matching medications currently found on file.

Baclofen

Generic Formulation: BaclofenSpecialty: Neurology
Provider Metrics Summary
Total Claims 12
30-Day Fills 26.0
Days Supply 780
NY State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills48.4
Peer Average Days Supply1,320
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 69.2% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $97.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.08

State Avg Cost Per Claim

$28.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A GAMMA-AMINOBUTYRIC ACID derivative that is a specific agonist of GABA-B RECEPTORS. It is used in the treatment of MUSCLE SPASTICITY, especially that due to SPINAL CORD INJURIES. Its therapeutic effects result from actions at spinal and supraspinal sites, generally the reduction of excitatory transmission.

Therapeutic Applications

Baclofen is used to treat muscle spasms caused by certain conditions (such as multiple sclerosis, spinal cord injury/disease). It works by helping to relax the muscles.

Dalfampridine Er

Generic Formulation: DalfampridineSpecialty: Neurology
Provider Metrics Summary
Total Claims 21
30-Day Fills 29.0
Days Supply 870
NY State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills58.7
Peer Average Days Supply1,716
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 54.3% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $20,091.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$956.74

State Avg Cost Per Claim

$820.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the POTASSIUM CHANNEL BLOCKERS with secondary effect on calcium currents which is used mainly as a research tool and to characterize channel subtypes.

Therapeutic Applications

Dalfampridine is used to improve walking in people with multiple sclerosis (MS). It is a potassium channel blocker. It is thought to work by improving nerve conduction.

Dimethyl Fumarate

Generic Formulation: Dimethyl FumarateSpecialty: Neurology
Provider Metrics Summary
Total Claims 18
30-Day Fills 20.0
Days Supply 600
NY State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills27.1
Peer Average Days Supply793
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $23,500.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,305.57

State Avg Cost Per Claim

$2,839.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fumarate derivative that is used as a DERMATOLOGIC AGENT in the treatment of PSORIASIS and SKIN DISEASES. It also may be used as an IMMUNOSUPPRESSIVE AGENT in the treatment of MULTIPLE SCLEROSIS.

Therapeutic Applications

Dimethyl fumarate is used to treat multiple sclerosis (MS). It is not a cure for MS. It helps decrease the number of episodes of worsening MS.

Glatiramer Acetate

Generic Formulation: Glatiramer AcetateSpecialty: Neurology
Provider Metrics Summary
Total Claims 34
30-Day Fills 34.0
Days Supply 976
NY State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills24.8
Peer Average Days Supply690
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 47.8% more claims than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $150,299.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,420.58

State Avg Cost Per Claim

$4,109.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A random polymer of L-ALANINE, L-GLUTAMIC ACID, L-LYSINE, and L-TYROSINE that structurally resembles MYELIN BASIC PROTEIN. It is used in the treatment of RELAPSING-REMITTING MULTIPLE SCLEROSIS.

Therapeutic Applications

This medication is used to treat multiple sclerosis (MS). It is a protein that is thought to work by preventing your immune system from attacking the nerves in your brain and spinal cord. This effect can decrease the number of periods of disease worsening (relapses) and prevent or delay disability. It is not a cure for MS.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. YAKOV ISAKOV provides transparency into local medical care patterns within New York, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Neurology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.